Rare diseases
Investigational molecules
Locations
706 conditions with trials, the busiest first
3 926 trials across Europe, recruiting first
Study of hu14.18K322A with temozolomide and irinotecan in children and adolescents with high‑risk neuroblastoma
DenmarkPhase III Randomized Study of Intravesical ALPHA1H as Neoadjuvant Therapy in Patients with Low- to Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer
CzechiaPhase 2 Study of PF-08634404 with Carboplatin and Etoposide in Adults with Untreated Small Cell Lung Cancer
FranceStudy of RMC-6291 with ivonescimab drug combination in patients with advanced RAS‑mutated solid tumors
BelgiumStudy of telisotuzumab adizutecan plus drug combination in adults with refractory metastatic colorectal cancer
BelgiumRandomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients
AustriaStudy of Enfortumab Vedotin and Pembrolizumab for Bladder Preservation in Patients with Muscle‑Invasive Bladder Cancer
FranceEpcoritamab for Adults with Relapsed or Refractory Marginal Zone Lymphoma: A Phase II Open‑Label Study
GermanySwitch maintenance with paclitaxel, ramucirumab and tislelizumab versus continued chemotherapy with tislelizumab in HER2‑negative, PD‑L1‑positive gastroesophageal cancer
GermanyPhase I/II Study of AZD6621 Safety and Efficacy in Adult Men with Metastatic Prostate Cancer
BelgiumStudy of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)
BelgiumPhase II Study of Teclistamab Plus Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma After 1–3 Prior Therapies
DenmarkThe therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
